AstraZeneca's Imfinzi shows sustained benefit in lung cancer study - Reuters
- AstraZeneca's Imfinzi shows sustained benefit in lung cancer study Reuters
- Durvalumab plus chemotherapy, without tremelimumab, extends OS in small cell lung cancer Healio
- Durable OS benefit boosts Imfinzi in lung cancer segment The Pharma Letter
- AZ's immunotherapy combo fails in phase 3 lung cancer trial - pharmaphorum
- AstraZeneca's Checkpoint Inhibitor Imfinzi Helps Overall Survival in Lung Cancer PharmaLive
- View Full Coverage on Google News
Comments
Post a Comment